



2 July 2025

ASX Announcement

Appointment of Jason Carroll as Non-Executive Chairman

MELBOURNE Australia, 2 July 2025: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to announce the appointment of Mr Jason Carroll as Non-Executive Chairman of the Board, commencing on 2 July 2025.

A highly regarded healthcare executive, Mr Carroll brings more than 30 years of experience in the field of life sciences and has held senior leadership roles at several multinational pharmaceutical companies including Johnson & Johnson, Janssen Pharmaceutica and iNova Pharmaceuticals.

Through his career background, Mr Carroll brings specialist expertise in both R&D and corporate strategy. His extensive experience in clinical product development includes oversight of successful market access and reimbursement programs for new drug treatments, alongside the delivery of regional M&A and business development strategies with a focus on South-East Asian markets.

Mr Carroll is a substantial shareholder in Island Pharmaceuticals and has been a long-term supporter of its pursuit to develop improved health solutions to combat dengue fever, providing strategic alignment with his appointment to oversee the Company's direction at Board level.

Whilst undertaking the role of Non-Executive Chairman of Island Pharmaceuticals Ltd Mr Carroll will continue to serve as CEO of Tryp Therapeutics Inc. (ASX:TYP), a clinical-stage biotechnology company dedicated to developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs.

Accompanying Mr Carroll's appointment, the Company announces that Mr Phil Lynch will step down from the Chairman role to focus on his other interests. Island sincerely thanks Mr Lynch for his contribution as Chairman and wishes him well in his future endeavours.

Incoming Non-Executive Chairman, Mr Jason Carroll, said: *I'm truly thrilled by the opportunity to join the Board of Island as the Company executes the next phase of clinical development. An effective solution for dengue fever remains a critical unmet need for half of the world's population, and I have, an unwavering belief in the potential of Island Pharmaceuticals to deliver an outcome that will help those in desperate need. I look forward to working closely with David and the Board in order to support the company and its shareholders as Island enters an exciting opportunity for growth."*



Island's CEO and Managing Director, Dr David Foster said: "We're delighted to welcome an industry leader of Jason's calibre as Chairman. With his wealth of experience and a strong track record in bringing clinically backed health care treatments, Jason is the ideal candidate to oversee the next phase of our commercialisation strategy at Board level, across both targeted M&A and the progression of clinical trials for ISLA-101. Concurrently, I'd like to acknowledge Phil's contribution to the Company as Chairman and wish him well for the future."

- Ends -

To subscribe to Island's monthly newsletter, [IslandWatch](#), and other forms of email communications, please visit [this page](#) of our website.

Approved for release to the ASX by:

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.